Cargando…

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival

INTRODUCTION: This study aimed to assess the effects of multiple docetaxel (DOC) treatments on prostate-specific antigen (PSA) kinetics and survival among patients with metastatic castration-resistant prostate cancer (mCRPC) who were sensitive to first-line DOC and received no other life-prolonging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maj-Hes, Agnieszka, Szarvas, Tibor, Sevcenco, Sabina, Kramer, Gero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280015/ https://www.ncbi.nlm.nih.gov/pubmed/34043207 http://dx.doi.org/10.1007/s12325-021-01778-8

Ejemplares similares

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer
por: Keresztes, Dávid, et al.
Publicado: (2021)

Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer
por: Csizmarik, Anita, et al.
Publicado: (2022)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer
por: Zhou, Tie, et al.
Publicado: (2015)

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
por: Heath, Elisabeth, et al.
Publicado: (2019)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
por: Wu, Kai-Jie, et al.
Publicado: (2018)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma
por: Guo, Zhaoxin, et al.
Publicado: (2022)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes
por: Cavo, Alessia, et al.
Publicado: (2018)

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
por: Eigl, Bernhard Josef, et al.
Publicado: (2018)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan
por: Chiang, Ping-Chia, et al.
Publicado: (2023)

Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
por: Min, Byung-Dal, et al.
Publicado: (2012)

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
por: Nakano, Kazuhiko, et al.
Publicado: (2014)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
por: Davis, Keith L., et al.
Publicado: (2015)

Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics
por: Deris, Atefeh, et al.
Publicado: (2023)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
por: Lim, Hyun-Kyung, et al.
Publicado: (2016)

A Comparison of Hepatocyte Cytotoxic Mechanisms for Docetaxel and PLGA-Docetaxel Nanoparticls
por: Daraei, Bahram, et al.
Publicado: (2017)

Effects of Docetaxel Injection and Docetaxel Micelles on the Intestinal Barrier and Intestinal Microbiota
por: Liu, Qingya, et al.
Publicado: (2021)

Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis
por: Mahal, Brandon A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ikib21s4l6pjr2h8p4rie9cgh